This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of LX1606 in subjects with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.